SCHEMBL5137888

SCHEMBL5137888

CCCCN(Cc1ccc(OC(F)(F)F)cc1)Cc1c(-c2ccc(Cl)cc2)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.41

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 4/20 0.41
MAPT P10636 1/20 0.41
ATP4A P20648 4/20 0.39
ATP4B P51164 4/20 0.39
C5AR1 P21730 1/20 0.39
PPARG P37231 1/20 0.39
PPARA Q07869 1/20 0.39
TRPM8 Q7Z2W7 1/20 0.36
DRD2 P14416 2/20 0.36
DRD3 P35462 2/20 0.36
HSD11B1 P28845 1/20 0.36
TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136208 0.95 CRHR1 (0.43) CRHR1ATP4AATP4BC5AR1PPARG
SCHEMBL5134950 0.90 C5AR1 (0.45) CRHR1MAPTATP4AATP4BC5AR1
SCHEMBL5135937 0.90 ATP4A (0.49) MAPTATP4AATP4BDRD2DRD3
SCHEMBL5135329 0.90 TP53 (0.46) CRHR1MAPTATP4AATP4BC5AR1
SCHEMBL5137477 0.90 CRHR1 (0.43) CRHR1MAPTC5AR1
SCHEMBL5138032 0.90 C5AR1 (0.43) CRHR1ATP4AATP4BC5AR1PPARG
SCHEMBL5136847 0.90 MAPT (0.44) CRHR1MAPTATP4AATP4BC5AR1
SCHEMBL5135824 0.90 C5AR1 (0.44) CRHR1MAPTATP4AATP4BC5AR1
SCHEMBL5136524 0.89 C5AR1 (0.46) CRHR1MAPTC5AR1
SCHEMBL5135885 0.89 MAPT (0.45) MAPTATP4AATP4BC5AR1DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed